Certolizumab pegol for treating axial spondyloarthritis

Julianna Desmarais, Secia Beier, Atulya (Atul) Deodhar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

ABSTRACT: Introduction: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease of the spine and sacroiliac (SI) joints. The spectrum of axSpA includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). Evidence has supported the use of TNF alpha inhibitors (TNFi) in treating these diseases, with good efficacy and tolerable safety profiles. Certolizumab pegol (CZP) is an anti-TNF alpha (TNFa) agent with data to support its use in both AS and nr-axSpA. Areas covered: The pharmacologic properties of CZP were reviewed. Data regarding the use and efficacy of CZP in axSpA were reviewed. Quality of life outcomes and safety profiles of CZP in axSpA patients were discussed as well. Expertopinion: While there are several biologics with evidence for improved outcomes in AS, there is less evidence for biologic medications that have good efficacy in nr-axSpA. CZP has good evidence of improved outcomes in terms of clinical efficacy, patient reported outcomes and imaging outcomes in both conditions, with a tolerable safety profile.

Original languageEnglish (US)
Pages (from-to)1059-1064
Number of pages6
JournalExpert Opinion on Biological Therapy
Volume16
Issue number8
DOIs
StatePublished - Aug 2 2016

Fingerprint

Ankylosing Spondylitis
Safety
Tumor Necrosis Factor-alpha
Sacroiliac Joint
Biological Products
Spine
Chronic Disease
Quality of Life
Certolizumab Pegol
Imaging techniques

Keywords

  • ankylosing spondylitis
  • Axial spondyloarthritis
  • certolizumab pegol
  • non-radiographic spondyloarthritis

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Certolizumab pegol for treating axial spondyloarthritis. / Desmarais, Julianna; Beier, Secia; Deodhar, Atulya (Atul).

In: Expert Opinion on Biological Therapy, Vol. 16, No. 8, 02.08.2016, p. 1059-1064.

Research output: Contribution to journalArticle

Desmarais, Julianna ; Beier, Secia ; Deodhar, Atulya (Atul). / Certolizumab pegol for treating axial spondyloarthritis. In: Expert Opinion on Biological Therapy. 2016 ; Vol. 16, No. 8. pp. 1059-1064.
@article{1cc62096bdaa48a28dddd36b646b9de3,
title = "Certolizumab pegol for treating axial spondyloarthritis",
abstract = "ABSTRACT: Introduction: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease of the spine and sacroiliac (SI) joints. The spectrum of axSpA includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). Evidence has supported the use of TNF alpha inhibitors (TNFi) in treating these diseases, with good efficacy and tolerable safety profiles. Certolizumab pegol (CZP) is an anti-TNF alpha (TNFa) agent with data to support its use in both AS and nr-axSpA. Areas covered: The pharmacologic properties of CZP were reviewed. Data regarding the use and efficacy of CZP in axSpA were reviewed. Quality of life outcomes and safety profiles of CZP in axSpA patients were discussed as well. Expertopinion: While there are several biologics with evidence for improved outcomes in AS, there is less evidence for biologic medications that have good efficacy in nr-axSpA. CZP has good evidence of improved outcomes in terms of clinical efficacy, patient reported outcomes and imaging outcomes in both conditions, with a tolerable safety profile.",
keywords = "ankylosing spondylitis, Axial spondyloarthritis, certolizumab pegol, non-radiographic spondyloarthritis",
author = "Julianna Desmarais and Secia Beier and Deodhar, {Atulya (Atul)}",
year = "2016",
month = "8",
day = "2",
doi = "10.1080/14712598.2016.1205581",
language = "English (US)",
volume = "16",
pages = "1059--1064",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Certolizumab pegol for treating axial spondyloarthritis

AU - Desmarais, Julianna

AU - Beier, Secia

AU - Deodhar, Atulya (Atul)

PY - 2016/8/2

Y1 - 2016/8/2

N2 - ABSTRACT: Introduction: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease of the spine and sacroiliac (SI) joints. The spectrum of axSpA includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). Evidence has supported the use of TNF alpha inhibitors (TNFi) in treating these diseases, with good efficacy and tolerable safety profiles. Certolizumab pegol (CZP) is an anti-TNF alpha (TNFa) agent with data to support its use in both AS and nr-axSpA. Areas covered: The pharmacologic properties of CZP were reviewed. Data regarding the use and efficacy of CZP in axSpA were reviewed. Quality of life outcomes and safety profiles of CZP in axSpA patients were discussed as well. Expertopinion: While there are several biologics with evidence for improved outcomes in AS, there is less evidence for biologic medications that have good efficacy in nr-axSpA. CZP has good evidence of improved outcomes in terms of clinical efficacy, patient reported outcomes and imaging outcomes in both conditions, with a tolerable safety profile.

AB - ABSTRACT: Introduction: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease of the spine and sacroiliac (SI) joints. The spectrum of axSpA includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). Evidence has supported the use of TNF alpha inhibitors (TNFi) in treating these diseases, with good efficacy and tolerable safety profiles. Certolizumab pegol (CZP) is an anti-TNF alpha (TNFa) agent with data to support its use in both AS and nr-axSpA. Areas covered: The pharmacologic properties of CZP were reviewed. Data regarding the use and efficacy of CZP in axSpA were reviewed. Quality of life outcomes and safety profiles of CZP in axSpA patients were discussed as well. Expertopinion: While there are several biologics with evidence for improved outcomes in AS, there is less evidence for biologic medications that have good efficacy in nr-axSpA. CZP has good evidence of improved outcomes in terms of clinical efficacy, patient reported outcomes and imaging outcomes in both conditions, with a tolerable safety profile.

KW - ankylosing spondylitis

KW - Axial spondyloarthritis

KW - certolizumab pegol

KW - non-radiographic spondyloarthritis

UR - http://www.scopus.com/inward/record.url?scp=84978976235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978976235&partnerID=8YFLogxK

U2 - 10.1080/14712598.2016.1205581

DO - 10.1080/14712598.2016.1205581

M3 - Article

VL - 16

SP - 1059

EP - 1064

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 8

ER -